REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 154 filers reported holding REATA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $11,773,525 | -28.3% | 115,472 | -36.0% | 1.88% | -49.7% |
| Q1 2023 | $16,416,879 | +114.8% | 180,564 | -10.3% | 3.72% | +102.0% |
| Q4 2022 | $7,643,588 | +89.4% | 201,200 | +25.3% | 1.84% | +129.6% |
| Q3 2022 | $4,035,000 | -27.4% | 160,564 | -12.2% | 0.80% | -20.7% |
| Q2 2022 | $5,555,000 | -77.4% | 182,805 | -75.7% | 1.01% | -68.7% |
| Q1 2022 | $24,629,000 | +211.3% | 751,805 | +150.6% | 3.24% | +174.6% |
| Q4 2021 | $7,911,000 | -86.5% | 300,000 | -48.4% | 1.18% | -71.3% |
| Q3 2021 | $58,450,000 | +136.1% | 581,000 | +232.2% | 4.12% | +105.6% |
| Q2 2021 | $24,755,000 | +135.3% | 174,900 | +65.8% | 2.00% | +465.3% |
| Q1 2021 | $10,519,000 | -48.9% | 105,500 | -36.7% | 0.35% | -61.0% |
| Q4 2020 | $20,596,000 | +21.2% | 166,600 | -4.5% | 0.91% | -26.2% |
| Q3 2020 | $17,000,000 | -56.6% | 174,500 | -30.4% | 1.23% | -60.5% |
| Q2 2020 | $39,130,000 | +116.9% | 250,800 | +100.6% | 3.11% | +129.5% |
| Q1 2020 | $18,043,000 | – | 125,000 | – | 1.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |